Drug intelligence / Profile preview

ganciclovir + mesalazine + papaverine

Development stage: Preclinical
Modality: Small Molecules
Administration: Intravenous, Oral, Rectal

Overview

A combination therapy used for treating severe ulcerative colitis complicated by cytomegalovirus colitis and microcirculatory disturbance. This specific combination was documented in a case study where ganciclovir was used as an antiviral agent for CMV colitis, mesalazine as an anti-inflammatory for ulcerative colitis, and papaverine was added as a vasodilator to address microcirculatory disturbance. The addition of papaverine resulted in dramatic improvement of symptoms that had been resistant to the initial treatments.

Targets

PDE (Phosphodiesterase family)LOX (Arachidonate 12-lipoxygenase, 12R-type)CMV DNA polymerase (Human cytomegalovirus DNA polymerase)

Beyond the preview

Go deeper on ganciclovir + mesalazine + papaverine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ganciclovir + mesalazine + papaverine.

Explore the full profile